Russia developed a new mRNA-based personalised cancer ‘vaccine’, expected to be available for free by early 2025.
Announced by Andrey Kaprin, General Director of the Radiology Medical Research Center of the Russian Ministry of Health.
Alexander Gintsburg, Director of the Gamaleya National Research Center, stated that pre-clinical trials showed suppression of tumour growth and metastases.
What is an mRNA Cancer ‘Vaccine’?
Uses messenger RNA (mRNA) to train the immune system to detect and attack cancer cells.
Unlike traditional vaccines that prevent diseases, these are designed to treat existing cancer.
A form of immunotherapy that enhances the body’s natural immune response to target tumours.
How Do These ‘Vaccines’ Work?
Cancer cells evade immune detection; mRNA therapy boosts the immune system to recognize and destroy them.
Personalised treatment—targets specific antigens unique to each patient’s tumour.
Potentially fewer side effects compared to chemotherapy, as it spares healthy cells.
Other Global Research on mRNA Cancer ‘Vaccines’
U.K.: NHS launched the Cancer Vaccine Launch Pad to accelerate clinical trials.
U.S.: CureVac’s CVGBM cancer vaccine showed promise in phase 1 trials for glioblastoma (brain cancer).
Over 120 clinical trials are underway globally.
Challenges and Concerns
Cancer is not caused by a single pathogen, unlike infectious diseases, making the term ‘vaccine’ potentially misleading.
HPV vaccine prevents cervical cancer, and Hepatitis B vaccine may help prevent liver cancer—but mRNA cancer ‘vaccines’ are not preventive.
Limited public data on Russia’s mRNA treatment—unclear at what stage the research is.
Clinical trials take years, so safety and effectiveness are still unknown.
Future Outlook
Immunotherapy shows promise but is not suitable for all cancers or all patients.
More research needed to determine long-term success and safety.
Time will tell how effective these personalised mRNA cancer ‘vaccines’ will be.
COMMENTS